These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30857522)

  • 1. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Itzhak B; Lalic N; Rahelic D; Skrha J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2019 Mar; 18(1):30. PubMed ID: 30857522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Lalic K; Skrha J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2018 Feb; 17(1):30. PubMed ID: 29458368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2016 Feb; 15():33. PubMed ID: 26892706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Rahelic D; Ceriello A
    Cardiovasc Diabetol; 2017 Mar; 16(1):35. PubMed ID: 28284218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report from the 5th cardiovascular outcome trial (CVOT) summit.
    Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
    Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
    Schnell O; Battelino T; Bergenstal R; Blüher M; Böhm M; Brosius F; Carr RD; Ceriello A; Forst T; Giorgino F; Guerci B; Heerspink HJL; Itzhak B; Ji L; Kosiborod M; Lalić N; Lehrke M; Marx N; Nauck M; Rodbard HW; Rosano GMC; Rossing P; Rydén L; Santilli F; Schumm-Draeger PM; Vandvik PO; Vilsbøll T; Wanner C; Wysham C; Standl E
    Cardiovasc Diabetol; 2022 Apr; 21(1):50. PubMed ID: 35395808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
    Schnell O; Cos X; Cosentino F; Forst T; Giorgino F; Heersprink HJL; Kosiborod M; Wanner C; Standl E
    Cardiovasc Diabetol; 2021 Mar; 20(1):75. PubMed ID: 33789663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
    Schnell O; Barnard-Kelly K; Battelino T; Ceriello A; Larsson HE; Fernández-Fernández B; Forst T; Frias JP; Gavin JR; Giorgino F; Groop PH; Heerspink HJL; Herzig S; Hummel M; Huntley G; Ibrahim M; Itzhak B; Jacob S; Ji L; Kosiborod M; Lalic N; Macieira S; Malik RA; Mankovsky B; Marx N; Mathieu C; Müller TD; Ray K; Rodbard HW; Rossing P; Rydén L; Schumm-Draeger PM; Schwarz P; Škrha J; Snoek F; Tacke F; Taylor B; Jeppesen BT; Tesfaye S; Topsever P; Vilsbøll T; Yu X; Standl E
    Cardiovasc Diabetol; 2024 Mar; 23(1):104. PubMed ID: 38504284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
    Schnell O; Battelino T; Bergenstal R; Birkenfeld AL; Ceriello A; Cheng A; Davies M; Edelman S; Forst T; Giorgino F; Green J; Groop PH; Hadjadj S; J L Heerspink H; Hompesch M; Izthak B; Ji L; Kanumilli N; Mankovsky B; Mathieu C; Miszon M; Mustafa R; Nauck M; Pecoits-Filho R; Pettus J; Ranta K; Rodbard HW; Rossing P; Ryden L; Schumm-Draeger PM; Solomon SD; Škrha J; Topsever P; Vilsbøll T; Wilding J; Standl E
    Cardiovasc Diabetol; 2023 Mar; 22(1):59. PubMed ID: 36927451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
    Schernthaner G; Lehmann R; Prázný M; Czupryniak L; Ducena K; Fasching P; Janež A; Karasik A; Kempler P; Martinka E; Shestakova MV; Duvnjak LS; Tankova T
    Cardiovasc Diabetol; 2017 Oct; 16(1):137. PubMed ID: 29061170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2016 Oct; 15(1):139. PubMed ID: 27716274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes.
    Sciannameo V; Berchialla P; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2021 May; 20(1):103. PubMed ID: 33971880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CVOTs: What did the endocrinologist learn?
    Valensi P; Prévost G
    Diabetes Res Clin Pract; 2020 Jan; 159():107947. PubMed ID: 31778747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?
    Rydén L; Mellbin L
    Curr Vasc Pharmacol; 2012 Nov; 10(6):690-2. PubMed ID: 23259555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
    Williams DM; Nawaz A; Evans M
    Diabetes Ther; 2020 Feb; 11(2):369-386. PubMed ID: 31863343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman J; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Cardiovasc Diabetol; 2018 Apr; 17(1):54. PubMed ID: 29636104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications.
    Hoogwerf BJ; Manner DH; Fu H; Moscarelli E; Gaydos BL; Heine RJ
    Diabetes Care; 2016 Aug; 39 Suppl 2():S219-27. PubMed ID: 27440836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ESC/EASD joint guidelines on diabetes and cardiovascular diseases].
    Motz W; Dörr R; ;
    Herz; 2009 Feb; 34(1):21-9. PubMed ID: 19214406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.